Pfizer, Inc. (NYSE:PFE)

CAPS Rating: 4 out of 5

A research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra.

Results 1 - 20 of 981 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar bobg304 (20.50) Submitted: 8/26/2015 12:36:49 PM : Outperform Start Price: $31.35 PFE Score: -1.52

great dividend a keeper

Recs

0
Member Avatar murphydevani (51.69) Submitted: 8/14/2015 4:14:35 AM : Outperform Start Price: $35.37 PFE Score: -3.25

Wonderful Pick $35.36 has not performed as per expectations Can reach $54.00 - $63 Levels...

Recs

0
Member Avatar srburnel (< 20) Submitted: 6/16/2015 5:33:45 PM : Outperform Start Price: $33.79 PFE Score: +2.05

Just a good company even in the lean pipeline years. This is when you get into a DRIP and accumulate shares.

Recs

0
Member Avatar BASSALDMF (60.33) Submitted: 2/10/2015 11:00:38 PM : Outperform Start Price: $33.46 PFE Score: +1.17

PIPELINE, NEW FDA APPROVAL.

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 11/14/2014 5:40:38 PM : Outperform Start Price: $28.44 PFE Score: +15.56

Div. (Yield) $1.04 (3.4%)

Recs

0
Member Avatar rwdewey (< 20) Submitted: 10/30/2014 1:59:04 PM : Outperform Start Price: $28.97 PFE Score: +13.02

As baby boomers continue to age, demand for everything Pfizer will continue to go up. Solid dividend history and price point is attractive to a broad range of investors

Recs

0
Member Avatar yeti6789 (59.33) Submitted: 10/23/2014 6:29:18 PM : Outperform Start Price: $27.86 PFE Score: +15.19

Stock repurchasing plan and a solid shot at beating estimates this quarter.

Recs

1
Member Avatar poerqwa (< 20) Submitted: 9/27/2014 1:41:36 PM : Underperform Start Price: $28.70 PFE Score: -12.25

The stock has been underperforming for a while now. AstraZeneca and other pharma-peers are showing a nice growth(in stock price). The recent fail of Pfizer to take over AstraZeneca(AZN) and nothing special in the works, only proves to me that for the foreseeable future the stock will underperform against it's peers.

Recs

0
Member Avatar tes1900 (< 20) Submitted: 9/12/2014 4:49:28 AM : Outperform Start Price: $28.51 PFE Score: +15.00

Another great player

Recs

0
Member Avatar boolanger (49.89) Submitted: 8/7/2014 4:04:14 PM : Outperform Start Price: $27.16 PFE Score: +16.18

High dividend yield with good balance sheet, 22 products in phase III research,

Recs

0
Member Avatar racoveanul (80.64) Submitted: 7/3/2014 1:44:03 PM : Outperform Start Price: $29.27 PFE Score: +11.04

I expect at least a point a week from this stock, for the next five years.

Recs

0
Member Avatar Gr8BigBoom (61.89) Submitted: 5/25/2014 10:29:34 AM : Outperform Start Price: $17.18 PFE Score: +29.24

The massive drug companies are shifting over to more addictive meds and just like the illegal drug trade, this will create med junkies. The docs know this, the gov knows this and a small percentage of people know this. When you can turn your customer into an addict for your product it's a win win situation.

Note: I am looking at this situation from an investors view only. Spare me the feelings stuff! I know what is happening is horrible when in a country of over 300 million people over 100 million use a major pain killer each day. I GET IT!

Recs

0
Member Avatar bingcroz (< 20) Submitted: 5/22/2014 10:29:30 AM : Outperform Start Price: $28.45 PFE Score: +9.83

Size matters when it comes to drugs

Recs

0
Member Avatar WHOVPLLC (39.56) Submitted: 4/30/2014 4:34:09 PM : Outperform Start Price: $29.54 PFE Score: +4.72

Pfizer is one of the old-time, Big-Pharma companies delivering increasing shareholder value through Research and Development, spin-offs of animal health units and selected acquisitions. These shares are a Long-term BUY.

WHOVPLLC
UWASAP.org

Recs

0
Member Avatar rhrehak (< 20) Submitted: 4/29/2014 2:49:21 PM : Outperform Start Price: $30.07 PFE Score: +2.55

Management will eventually get their act together

Recs

0
Member Avatar iPittytheFool (60.40) Submitted: 3/13/2014 6:46:38 PM : Outperform Start Price: $29.60 PFE Score: +2.51

I hate them... but spring time biotech picks are free points.

Recs

0
Member Avatar tcampbellla (81.19) Submitted: 2/17/2014 8:00:52 PM : Underperform Start Price: $30.23 PFE Score: +0.14

As sleazy as your neighborhood drug dealer.

Recs

0
Member Avatar rocker20 (25.51) Submitted: 2/11/2014 10:01:55 AM : Outperform Start Price: $29.89 PFE Score: -1.17

Outstanding performance and products

Recs

0
Member Avatar dj2000a (79.40) Submitted: 1/3/2014 3:40:38 PM : Outperform Start Price: $28.77 PFE Score: +4.59

Small dog of the DOW for 2014

Recs

0
Member Avatar TMFEBCapital (64.40) Submitted: 9/3/2013 8:57:09 AM : Outperform Start Price: $26.54 PFE Score: +2.46

Investments in ADC based oncology offer opportunity to boost pipeline.

Featured Broker Partners


Advertisement